BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24725667)

  • 1. Personalized medicine: present and future of breast cancer management.
    Sabatier R; Gonçalves A; Bertucci F
    Crit Rev Oncol Hematol; 2014 Sep; 91(3):223-33. PubMed ID: 24725667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating DNA as biomarker in breast cancer.
    Schwarzenbach H; Pantel K
    Breast Cancer Res; 2015 Oct; 17(1):136. PubMed ID: 26453190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancements in Biotechnology and Stem Cell Therapies for Breast Cancer Patients.
    Dhoundiyal S; Alam MA
    Curr Stem Cell Res Ther; 2024; 19(8):1072-1083. PubMed ID: 37815191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized Cancer Care: Risk Prediction, Early Diagnosis, Progression, and Therapy.
    Zänker KS; Borresen-Dale AL; Huber HP
    Biomed Hub; 2016; 1(3):1-9. PubMed ID: 31988890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Validation of the genomic profile for personalized breast cancer treatment: POLAR study].
    Cieslak AM; Sonnhoff MA
    Strahlenther Onkol; 2024 Jul; 200(7):652-654. PubMed ID: 38743274
    [No Abstract]   [Full Text] [Related]  

  • 6. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy.
    Norum JH; Andersen K; Sørlie T
    Br J Surg; 2014 Jul; 101(8):925-38. PubMed ID: 24849143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How many etiological subtypes of breast cancer: two, three, four, or more?
    Anderson WF; Rosenberg PS; Prat A; Perou CM; Sherman ME
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25118203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?
    Sonnenblick A; Fumagalli D; Sotiriou C; Piccart M
    Cancer Treat Rev; 2014 Oct; 40(9):1089-95. PubMed ID: 25151406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
    Coates AS; Winer EP; Goldhirsch A; Gelber RD; Gnant M; Piccart-Gebhart M; Thürlimann B; Senn HJ;
    Ann Oncol; 2015 Aug; 26(8):1533-46. PubMed ID: 25939896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive biomarkers in breast cancer: Past, present and future.
    Nicolini A; Ferrari P; Duffy MJ
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):56-73. PubMed ID: 28882552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor cells in breast cancer: applications in personalized medicine.
    Lee JS; Magbanua MJM; Park JW
    Breast Cancer Res Treat; 2016 Dec; 160(3):411-424. PubMed ID: 27761678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalised cancer medicine.
    Jackson SE; Chester JD
    Int J Cancer; 2015 Jul; 137(2):262-6. PubMed ID: 24789362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards Agility in Breast Cancer Treatment Principles as Adopted from Agile Software Engineering.
    Odeh Y; Al-Balas M
    J Multidiscip Healthc; 2024; 17():1315-1341. PubMed ID: 38545433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of Agile Values in Software Engineering for Agility in Breast Cancer Treatment: Protocol for a Comparative Study.
    Odeh Y; Al-Balas M
    JMIR Res Protoc; 2023 Dec; 12():e53124. PubMed ID: 38051558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential roles of lncRNA TINCR in triple negative breast cancer.
    Azman AA; Siok-Fong C; Rajab NF; Md Zin RR; Ahmad Daud NN; Mohamad Hanif EA
    Mol Biol Rep; 2023 Sep; 50(9):7909-7917. PubMed ID: 37442895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Prognostic Biomarkers for Breast Cancer Metastasis Using Penalized Additive Hazards Regression Model.
    Tapak L; Hamidi O; Amini P; Afshar S; Salimy S; Dinu I
    Cancer Inform; 2023; 22():11769351231157942. PubMed ID: 36968522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients' Age: A Retrospective Cohort Study.
    Massafra R; Bove S; La Forgia D; Comes MC; Didonna V; Gatta G; Giotta F; Latorre A; Nardone A; Palmiotti G; Quaresmini D; Rinaldi L; Tamborra P; Zito A; Rizzo A; Fanizzi A; Lorusso V
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics'.
    Mehmood S; Faheem M; Ismail H; Farhat SM; Ali M; Younis S; Asghar MN
    Front Mol Biosci; 2022; 9():783494. PubMed ID: 35495618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Illness Perception and Quality of Life in Patients with Breast Cancer.
    Ośmiałowska E; Staś J; Chabowski M; Jankowska-Polańska B
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.